

Spotlight on fluticasone furoate/vilanterol trifenate for the once-daily treatment of asthma: design, development and place in therapy

Timothy E Albertson¹⁻³
Samuel W Bullick^{1,3}
Michael Schivo¹
Mark E Sutter^{2,3}

¹Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, ²Department of Emergency Medicine, School of Medicine, UC Davis, Sacramento, ³Department of Medicine, Veterans Administration Northern California Health Care System, Mather, CA, USA

Abstract: The use of inhaled corticosteroids (ICSs) plays a key role in the treatment of asthmatic patients, and international guidelines have designated ICSs as an early maintenance therapy in controlling asthma symptoms. When asthmatic patients remain symptomatic on ICSs, one common option is to add a long-acting beta₂ agonist (LABA) to the maintenance treatment. Fixed combination inhalers that contain both an ICS and a LABA have been popular for both chronic obstructive pulmonary disease (COPD) and asthma. Historically, these inhalers have been dosed twice daily. However, currently, there is a once-daily combination therapy with the ICS fluticasone furoate (FF) and the LABA vilanterol trifenate (VI) with indications for use in both COPD and asthma. This dry powder inhaler (DPI) comes in two doses of FF (100 or 200 µg) both combined with VI (25 µg). This article reviews the clinical trial data for FF, VI and FF/VI combination inhalers and documents the efficacy and safety of once-daily inhaled maintenance therapy by DPI in asthmatic patients.

Keywords: fluticasone furoate/vilanterol trifenate, asthma, long-acting beta₂ agonist, inhaled corticosteroid, combined inhaler, persistent asthma, dry powder inhaler

Introduction

Asthma is an airway disease of inflammation and bronchoconstriction. Genetics and environmental factors combine to produce different asthma phenotypes and various responses to controller medications. The Global Initiative for Asthma (GINA) updated in 2016¹ is an ongoing international effort to provide a unified approach to the diagnosis and treatment of asthma. Table 1 summarizes the GINA general treatment approach to asthma that uses a stepwise function based on the severity of asthma symptoms. The table shows that inhaled corticosteroids (ICSs) play a major role as maintenance or preventative treatments in this stepwise approach to asthma. Table 2 summarizes the currently available and approved handheld inhalers by the US Food and Drug Administration (FDA) and several others not available in the USA. Fluticasone furoate (FF) is a potent corticosteroid that is dosed once daily due to its long half-life when inhaled. It was approved by the FDA as a once-daily ICS for the maintenance treatment of asthma as a dry powder inhaler (DPI) in August 2014 with the brand name Arnuity™ Ellipta® (GSK, USA).²

Controversy exists as to the role of long-acting beta₂ agonists (LABAs) in the maintenance treatment of moderate to severe asthmatics. Early clinical trials of the LABA salmeterol (SAL) noted a nonstatistically significant increase in all-cause mortality in asthmatic patients treated over 16 weeks when compared to those using

Correspondence: Timothy E Albertson
Department of Internal Medicine,
Division of Pulmonary, Critical Care
and Sleep Medicine, School of Medicine,
UC Davis, 4150 V Street, Suite 3100,
Sacramento, CA, 95817, USA
Email tealbertson@ucdavis.edu

Table 1 The 2016 stepwise approach to asthma treatment¹

Asthma step	As-needed SABA	Low-dose ICS preferred controller	Medium/high-dose ICS/LABA	LTRA or Theo	Tiotropium	Alternative
Step 1	+	+				
Step 2	+	+		+		
Step 3	+ ^a	+ ^b	+ ^b	+		+ ^c
Step 4	+ ^a		+	+	+ ^d	+ ^e
Step 5	+ ^a		+	+	+ ^d	+ ^f

Notes: Adapted from GINA 2016.¹ ^aMay also include a single low-dose ICS/formoterol as a reliever medication for patients prescribed low-dose BUD/F for maintenance or low-dose BEC/F for those patients using BEC/F for maintenance. ^bPreferred step 3 maintenance for children aged 6–11 years is medium-dose ICS; adolescent/adults, low-dose ICS/LABA option. ^cMedium/high-dose ICS, low-dose ICS + LTRA, low-dose ICS + Theo are alternate options. ^dTiotropium (LAMA) by spring-driven mist (not indicated in children aged < 12 years). ^eTiotropium (LAMA) by spring-driven mist, high-dose ICS and LTRA or Theo are alternate options. ^fRefer to asthma specialist for add-on treatment options including tiotropium (LAMA), omalizumab, mepolizumab and/or oral corticosteroids.

Abbreviations: BEC/F, beclomethasone dipropionate/formoterol; BUD/F, budesonide/formoterol; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroids; LABA, long-acting beta₂ agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; SABA, short-acting beta₂ agonist; Theo, theophylline.

the short-acting beta₂ agonist (SABA), albuterol.³ A large 2006 clinical trial of 26,355 asthmatics named the Salmeterol Multicenter Asthma Research Trial (SMART) evaluated SAL by metered dose inhaler (MDI) compared to placebo MDI over 28 weeks.⁴ The use of ICS and leukotriene modifiers was equal in both groups (47% and 11%, respectively). The primary outcome included respiratory-related deaths or life-threatening events, and both were infrequent for the SAL group (50 patients) and placebo group (36 patients). This difference did not reach statistical significance (relative risk [RR]=1.40, 95% confidence interval [CI]=0.91–2.14). When secondary outcomes were explored, a small but significant increase in respiratory-related deaths was found in the SAL group (SAL 24 vs placebo 11; RR =2.16, 95% CI =1.06–4.41) along with specific asthma-related deaths (SAL 13 vs placebo 3; RR =4.37, 95% CI =1.25–15.4). The secondary outcome imbalances were largely related to the effects on the African-American subpopulation (20 SAL vs 5 placebo; RR =4.92, 95% CI =1.54–10.90).⁴ This study and a few others resulted in the FDA requiring a “black box” warning for all inhaled LABA agents based on the “risk” of their use in asthma.

Recent studies have called into question if there is an increase in risk to asthmatic patients treated with a combination ICS/LABA inhaler. In 2016, Peters et al⁵ studied 11,693 adult and adolescent asthmatic patients ≥12 years of age for 26 weeks. They were randomized to the ICS budesonide alone or a fixed-dose combination of budesonide and the LABA formoterol given twice daily by MDI. The budesonide/formoterol (BUD/F) combination was found to be noninferior to budesonide alone with 43 patients having a serious asthma-related event in the BUD/F group and 40 patients in the budesonide-alone-treated group (hazard ratio [HR]=1.07, 95% CI =0.70–1.65). The risk of an asthma exacerbation was

16.5% lower in the BUD/F-treated group compared to the budesonide-alone-treated group (HR =0.84, 95% CI =0.74–0.94).⁵ A similarly designed study in 11,679 asthmatic patients ≥12 years of age treated for 26 weeks also found that the combined fixed-dose fluticasone propionate (FP)/SAL did not have a significantly higher risk of serious asthma-related events and did have a 21% reduction in severe asthma exacerbations than those treated with fluticasone alone.⁶ Similarly, when a fixed combination inhaler of SAL and FP was compared to inhaled FP alone in 6,208 asthmatic children aged 4–11 years, non-inferiority for serious asthma-related events was seen (HR =1.28, 95% CI =0.73–2.27).⁷ These and other data suggest that the combination of an ICS with LABA is a safe and an effective treatment for asthma. Furthermore, the use of both an ICS and a LABA is an integral part of the GINA guidelines (Table 1) for the asthma patient at the step 3–step 5 levels.¹ Table 2 summarizes the multiple handheld inhalers available in the USA. At this time, LABA monotherapy without the simultaneous use of an ICS is still discouraged and has recently been described as “medical negligence” in children with asthma.⁸

The fixed combination of FF (100 or 200 µg) combined with the LABA vilanterol trifenate (VI; 25 µg) was approved in the USA in May 2013 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) as the once-daily DPI Breo Ellipta® (GSK, USA). The same year, the same combination of drugs, doses and delivery system (Relvar Ellipta®; GSK, UK) was approved in Japan and the European Union for the treatment of asthma.⁹ Breo Ellipta (FF [100 or 200 µg]/VI [25 µg]) was approved by the FDA for the maintenance treatment of asthma in April 2015.² This article reviews the data that support the use of the fixed-dose combination of DPI FF with VI as a once-daily asthma maintenance treatment.

Table 2 Major handheld inhaler therapy in asthma and COPD

Category	Drug	Dose (μ g)	Additional drug	Dose (μ g)	Frequency	Type	Examples of brand name
SABA	Albuterol sulfate	90	None	N/A	prn, q6h	MDI	Proventil HFA [®]
	Albuterol sulfate	90	None	N/A	prn, q6h	MDI	Ventolin HFA [®]
	Albuterol sulfate	90	None	N/A	prn, q6h	MDI	ProAir HFA [®]
	Albuterol sulfate	90	None	N/A	prn, q4–6h	DPI	ProAir RespiClick [®]
	Albuterol sulfate (salbutamol) ^a	100 and 200	None	N/A	prn, q6h	DPI	Easyhaler Salbutamol [®]
	Levalbuterol tartrate	45	None	N/A	prn, q6h	MDI	Xopenex HFA [®]
	Formoterol fumarate ^b	12	None	N/A	Twice daily	DPI	Foradil [®]
	Formoterol fumarate ^c	12	None	N/A	Twice daily	DPI	Atimos Modulite [®]
	SAL xinafoate	50	None	N/A	Twice daily	DPI	Serevent Diskus [®]
	SAL xinafoate ^a	25	None	N/A	Twice daily	MDI	Neovent [®]
SAMA	Indacaterol maleate ^d	75	None	N/A	Daily	DPI	Arcapta [®]
	Indacaterol maleate ^c	150 and 300	None	N/A	Once daily	DPI	Onbrez Breezhaler [®]
	Olodaterol hydrochloride ^d	2.5	None	N/A	Daily	SDM	Striverdi Respimat [®]
	Ipratropium bromide ^{e,f}	21	None	N/A	q6h	MDI	Atrovent HFA [®]
	Tiotropium bromide ^d	18	None	N/A	Daily	DPF	Spiriva HandiHaler [®]
	Tiotropium bromide ^d	2.5	None	N/A	Daily	SDM	Spiriva Respimat [®]
	Tiotropium bromide	1.25	None	N/A	Daily	SDM	Spiriva Respimat [®]
	Acclidinium bromide ^d	400	None	N/A	Twice daily	DPI	Tudorza Pressair [®]
	UMEC bromide ^d	62.5	None	N/A	Daily	DPI	Incruse Ellipta [®]
	Glycopyrrolate bromide ^c	50	None	N/A	Daily	DPI	Seebri Breezhaler [®]
Combination of SABA + SAMA	Albuterol sulfate ^{e,f}	100	Ipratropium bromide	30	q6h	SDM	Combivent Respimat [®]
	Tiotropium bromide ^d	2.5	Olodaterol	2.5	Daily	SDM	Stiolto Respimat [®]
	Acclidinium bromide ^c	400	Formoterol	12	Twice daily	DPI	Duaklir Genuair [®]
	UMEC bromide ^d	62.5	VI	25	Daily	DPI	Anora Ellipta [®]
	Glycopyrrolate bromide ^d	15.6	Indacaterol	27.5	Twice daily	DPI	Ultibro Neohaler [®]
	Glycopyrrolate bromide ^c	50	Indacaterol	110	Daily	DPI	Ultibro Breezhaler [®]
	Glycopyrrolate bromide ^d	9	Formoterol	4.8	Twice daily	MDI	Bevespi Aerosphere [®]
	Beclomethasone dipropionate	40 and 80	None	N/A	Twice daily	MDI	QVAR HFA [®]
	Budesonide	90 and 180	None	N/A	Twice daily	DPI	Pulmicort Flexhaler [®]
	Ciclesonide	80 and 160	None	N/A	Twice daily	MDI	Alvesco HFA [®]
Combination of ICS + LABA	FP	50, 100 and 250	None	N/A	Twice daily	DPI	Flovent Diskus [®]
	FP	44, 110 and 220	None	N/A	Twice daily	MDI	Flovent HFA [®]
	FP	100 and 200	None	N/A	Daily	DPI	Arnuity Ellipta [®]
	Mometasone furoate	110 and 220	None	N/A	Daily and twice daily	DPI	Asmanex Twisthaler [®]
	Budesonide	80 and 160	Formoterol fumarate	4.5	Twice daily	MDI	Symbicort [®]
	Budesonide ^a	160 and 320	Formoterol fumarate	4.5/9	Twice daily	DPI	DuoResp SpiroMax [®]
	FP	100, 250 and 500	SAL xinafoate	50	Twice daily	DPI	Advair Diskus [®]
	FP	45, 115 and 500	SAL xinafoate	21	Twice daily	MDI	Advair HFA [®]
	FP	100 and 200	VI	25	Daily	DPI	Breo Ellipta [®]
	Mometasone furoate	100 and 200	Formoterol fumarate	5	Twice daily	MDI	Dulera [®]

Notes: ^aApproved in the UK and Europe for COPD and asthmatic patients. ^bNo longer manufactured and sold in the USA but still FDA approved, still available in the UK/Europe. ^cApproved in the UK, Europe and Canada for COPD, not routinely used in asthmatic patients. ^dApproved by the FDA only for COPD, not routinely used in asthmatic patients. ^eUsed in acute exacerbations of asthma. ^fq6h, every 6 hours; prn, as needed.

Abbreviations: COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FDA, US Food and Drug Administration; FF, fluticasone furoate; FP, fluticasone propionate; ICS, inhaled corticosteroid; LABA, long-acting beta₂ agonist; LAMA, long-acting muscarinic antagonist; MDI, metered dose inhaler; N/A, not applicable; SABA, short-acting beta₂ agonist; SAL, salmeterol; SAMA, short-acting muscarinic antagonist; SDM, spring-driven mist; UMEC, umecidinium; VI, vilanterol trifenate.

FF in asthma

The inhaled use of FF in asthma is in part based on its long half-life in the lung that allows once-daily dosing for asthma maintenance therapy.¹⁰ As given in Table 1, ICS therapy plays a major role in the current GINA guidelines. When as-needed SABAs become inadequate to control asthma symptoms, the use of low-dose ICS should be considered as early as step 1 and used through step 2 into step 3 as medium- to high-dose ICS. The 100 µg daily DPI dose of FF is considered low-dose ICS therapy for asthmatics aged 12 years and older.¹ After the addition of a LABA to low-dose ICS therapy at step 3, higher medium- or high-dose ICS therapy is recommended by the GINA guidelines for asthmatic patients that remain symptomatic. The 200 µg daily DPI dose of FF is considered a “high-dose” ICS and can be used for symptomatic step 3–5 asthmatic patients.¹

Table 3 summarizes the major clinical trials that have examined the use of FF as an ICS maintenance asthma therapy. Efficacy and safety have been verified with once-daily FF dosing in asthmatic patients in several studies. An 8-week study of 545 adolescent and adult asthmatic patients demonstrated significant (all $P \leq 0.033$) improvements with FF in pre-dose and placebo-adjusted forced expiratory volume at 1 second (FEV_1). Once-daily evening-dosed FF (400 µg) was also as effective as twice-daily dosing (200 µg) of the same total daily FF dose in improving placebo-adjusted FEV_1 (≥ 200 mL).¹¹ In this study, the morning-dosed FF (400 µg) was found to be less effective than an equal dose of FF (200 µg) given twice daily (202 mL improvement, 95% CI =96–307 vs 315 mL improvement, 95% CI =208–421 mL).¹¹ A randomized, double-blind, double-dummy and placebo-controlled study further evaluated once-daily FF (100 µg) given in the morning compared to the evening over a 2-week trial in asthmatics aged 18–70 years who required an ICS to control symptoms.¹² Inhaled FF (100 µg) daily increased 24-hour weighted mean FEV_1 relative to placebo (for AM dosing, 77 mL; 90% CI =1–152 mL and for PM dosing, 105 mL; 90% CI =29–180 mL)¹³ and found that the difference in the increase when FF was given in the morning or evening was negligible (adjusted differences, 28 mL; 90% CI =–102–45 mL).¹² A longer 24-week multicenter, double-blind, parallel-group study compared once-daily evening doses of FF (100 µg) to FF (200 µg).¹³ Both FF doses improved least-squares mean trough FEV_1 from baseline by 208 mL in the FF (100 µg) group and 284 mL in the FF (200 µg) group (treatment difference, 77 mL; 95% CI =–39–192 mL).¹³ Similar improvements were seen in rescue- and symptom-free days, morning and evening peak

Table 3 Major clinical trials with FF in asthma

Study	Trial number	N	Drugs (µg)	Design	Results (doses in µg)
Bateman et al ⁶¹	NCT00603382	598	FF (25, 50, 100 or 200) qpm or FP (100) bid or P	≥ 12 -year-old asthmatics; MC, R, DB, DD, PC, PG, $\times 8$ weeks	A dose-response effect on FEV_1 was seen ($P < 0.001$) for FF. FF (50–200) significantly ($P < 0.05$) improved FEV_1 from baseline compared to P. FF non-inferior to FP
Woodcock et al ¹³	NCT01431950	238	FF (100 or 200) daily	≥ 12 -year-old asthmatics uncontrolled on mid-high-dose ICS; MC, R, DB, PG, $\times 24$ weeks	Least-squares mean trough FEV_1 was improved from baseline for both doses of FF. No significant difference between FF (100) and FF (200). Similar rates of AEs. No clinically relevant effects on
Lötvall et al ⁶²	NCT01159912	343	FF (100) qpm or FP (250) bid or P	≥ 12 -year-old asthmatics uncontrolled on ICS; MC, R, DB, DD, PC, PG, $\times 24$ weeks	24-hour urinary cortisol excretion at week 24 by either FF dose Both FF and FP significantly ($P = 0.01$) increased pre-dose evening FEV_1 compared to P at week 24. Less use of rescue medications with FF compared to P ($P < 0.001$). AEs were similar. Week 24 urinary cortisol levels were significantly reduced ($P = 0.036$) by both FF and FP compared to P
Busse et al ⁶³	NCT01436110	347	FF (50) qpm or FP (100) bid or P	≥ 12 -year-old asthmatics uncontrolled by non-ICS therapy; MC, R, DB, DD, PC, PG, $\times 24$ weeks	Evening trough FEV_1 at week 24 was not significantly increased with FF (50) but increased with FP (100) bid ($P = 0.03$). No safety concerns were noted
O'Byrne et al ⁶⁴	NCT01436071	248	FF (50) or P qpm	≥ 12 -year-old asthmatics; MC, R, DB, PC, PG, $\times 12$ weeks	Significant ($P = 0.012$) increase in evening trough FEV_1 with FF compared to P. Significant increase in rescue-free 24-hour periods ($P = 0.004$) with FF compared to P. Lower AEs with FF (31%) than P (38%)

Woodcock et al ¹¹	NCT00398645	646	FF (200 or 400) qam or FF (200 or 400) qpm or FF (200) or P bid all by DPI	≥12-year-old asthmatics; MC, R, DB, PC, ×8 weeks	All five FF dose groups produced significant ($P<0.05$) increases in pre-dose FEV ₁ compared to P. No difference between qd and bid dosing. Low incidence (0%–4%) of oral candidiasis and no differences in urinary cortisol excretion. Day 28 pre-dose FEV ₁ showed non-inferiority between FF (100) bid versus FF (200) qpm. All doses of FF and FF were superior to P ($P<0.02$). AEs were similar to P. Urinary cortisol excretion at day 28, lower for FF than for P ($P\leq 0.02$). Trough PEF improved with all doses of FF compared to P ($P\leq 0.005$). No difference in trough PEF with FF (100) qam or qpm. No serious AEs. No dose–response effect was seen across the FF doses studied. All FF doses improved PEF ($P<0.001$) compared to P. Incidence of oral candidiasis increased compared to P with the FF (800) dose. FF (500) bid also improved PEF. Trough FEV ₁ improved with FF (100) alone but > with FF (100) + UMEC (125 or 250). FF/UMEC increased morning and evening PEF compared to FF (100) alone. AEs were similar across groups, and no laboratory parameter changes were noted.
Woodcock et al ⁶⁵	NCT00766090	190	All patients received bid dosing – if listed as qd – second daily dose was P. FF (100) bid or FF (200) qpm or FF (200) qpm or FF (100) bid or P bid FF (100) qam or FF (100) qpm or FF (250) qpm or P	≥12-year-old asthmatics; MC, R, XO, PC, XO, ×4 weeks	
Medley et al ⁶⁶	NCT01499446	575	FF (200, 400, 600 or 800) qpm, FF (500) bid, P qpm	Asthmatic patients aged 16–55 years; MC, R, DB, DD, PC, PG, ×4 weeks	
Busse et al ⁶⁷	NCT00063746	627	FF (100) qam or FF (100) + UMEC (15.6, 31.25, 62.5, 125 or 250) qam or FF (100) + VI (25) qam	≥12-year-old asthmatics uncontrolled on ICS; MC, R, DB, DD, PC, PG, ×8 weeks	
Lee et al ¹⁴	NCT01573624	421	FF (100) qam + P qpm or P qam + FF (100) qpm or P qam + P qpm	≥18-year-old asthmatics on ICS; MC, R, DB, XO, ×2 weeks	
Kempford et al ¹²	NCT01808339	21	FF (100, 200, 300 or 400) qpm or FF (250) bid or P bid	18–70-year-old asthmatics on ICS; SC, R, DB, DD, PC, XO, ×2 weeks	FF (100) increased 24-hour weighted mean FEV ₁ . The increases for FF dosed in the AM or PM were comparable. No serious AEs were reported.
Bleecker et al ⁶⁸	NCT 00603278	622	Single dose – P or FF (1,000) – 2, 14 or 26 hours or FF (1,000) – 14 or 26 hours before AmpCT	≥12-year-old asthmatics; MC, R, DB, DD, PC, PG, ×8 weeks	Significant ($P<0.001$) greater increase in FEV ₁ with all doses of FF and FP than P. Increases with qd FF were equal or greater than with bid FF. The 24-hour urinary cortisol levels were similar with all doses of FF, FP and P.
van den Berge et al ⁶⁹	Not given	24	Single dose – FF (400) or UMEC (500) or FF (400) plus UMEC (500)	Asthmatic patients not on ICS; MC, R, DB, PC, XO	Threshold dose AmpCT increased by prior exposure to FF at 2, 14 or 26 hours compared to P. Prior FP exposure only increased AmpCT threshold at 14 hours not at 26 hours compared to P.
Yang et al ¹⁵	NCT01725685	18	FF (250) intravenous or FF (800) or FF (400) both by DPI	18–65-year-old healthy volunteers; SC, R, DB, XO	Plasma FF concentrations peaked at 0.5 hours alone and with combined FF/UMEC inhaler. No clinically significant AEs, vital signs or laboratory parameters.
Allen et al ⁷⁰	NCT01000597	80	FF (250) intravenous or FF (800) or FF (400) both by DPI	20–59-year-old healthy Caucasian, Japanese, Korean and Chinese subjects; OL, R, XO, single and daily repeat doses ×7 days; intravenous dose ×1 only	Higher FF systemic exposures were seen in Chinese, Japanese and Korean subjects compared to Caucasian subjects. Bioavailability was higher in Asian subjects than Caucasian. Japanese had on average 22% lower serum weighted mean cortisol levels than Caucasians, Chinese or Koreans. Serum weighted mean cortisol levels were similar in Caucasians, Chinese or Koreans. Well tolerated in all groups.

Notes: References in bold are key studies; bid, twice daily; qam, daily morning; qd, once daily; qpm, daily evening.

Abbreviations: AEs, adverse events; AmpCT, adenosine 5'-monophosphate (AMP) challenge test; DB, double blind; DD, double blind; DPI, dry powder inhaler; FEV₁, forced expiratory volume in 1 second; FF, fluticasone furoate; FP, fluticasone propionate; ICS, inhaled corticosteroid; MC, multiple centers; NCT, clinical trials.gov study numbers; OL, open label; P, placebo; PC, placebo controlled; PEF, peak expiratory flow; PG, parallel group; R, randomized; SC, single center; UMEC, umecidinium; VI, vilanterol trifenate; XO, crossover.

expiratory flow (PEF) and reported adverse events with the two FF doses. The 200 µg FF-treated group was 42% more likely to have well-controlled symptoms than the 100 µg FF-treated group. There were no safety concerns, and no clinically relevant effects on 24-hour urinary cortisol levels with either of the doses of inhaled FF were found.¹³

When inhaled FF (100 µg) daily for 2 weeks was compared to FF (100 µg) combined with the long-acting muscarinic antagonist (LAMA), umeclidinium (UMEC; 15.6, 31.25, 62.5, 125 or 250 µg), in adult asthmatics, trough FEV₁ was improved with FF (100 µg) alone (by 87 mL) compared to baseline, but they increased even more when FF (100 µg) was combined with UMEC doses (141–214 mL).¹⁴ When least-squares mean change in trough FEV₁ was evaluated, statistically significant differences were seen with FF (100 µg)/UMEC (125 and 250 µg; both 55 mL, $P=0.018$) compared to FF (100 µg) alone.¹⁴ In addition, both morning and evening PEF improved more with the combination of FF with UMEC daily inhalation compared to FF alone. The FF serum concentrations peaked at half an hour when given alone, and this did not change when combined with UMEC.¹⁵ The use of daily FF given by DPI has a proven efficacy in asthmatic patients requiring an ICS for symptom control. The combination of FF with LAMA appears to increase the efficacy compared to FF alone in asthmatic patients.

The use of VI in asthma

Several new LABA agents designed for once-daily dosing are available or under study including indacaterol, olodaterol, abediterol and VI.¹⁶ Appropriate concern for the use of LABA agents alone as maintenance therapy has mandated that asthmatic subjects in most clinical studies evaluating the use of the inhaled LABA VI be currently on an ICS (Table 4). An exception is the study by Kempsford et al.¹⁷ Inhaled VI was given once daily (25–100 µg) for 14 days to healthy volunteers and once to patients with either asthma or COPD. Inhaled VI was rapidly absorbed with a median time to maximal serum concentrations of 5 minutes in healthy subjects and 10 minutes for asthma and COPD patients. All VI doses improved FEV₁ by 5 minutes and maintained increased FEV₁ up to 24 hours after inhalation in patients with asthma or COPD.¹⁷ No clinically significant adverse effects were found including evaluations of vital signs, 12-lead electrocardiogram (ECG), Holter ECG, blood glucose or potassium levels. Table 4 summarizes five placebo-controlled clinical trials in asthmatics on an ICS that evaluated inhaled VI using a DPI device lasting between 1 and 12 weeks. Doses between 3 and 50 µg daily of inhaled VI were tried, and the bronchodilator effect lasted at least 24 hours for

VI doses 12.5–50 µg.¹⁸ The efficacy and safety of once-daily VI dosing in asthmatics were established by Sterling et al¹⁹ who evaluated 72 adult (≥ 18 years old) asthmatics on an ICS with a 7-day treatment of daily inhaled VI (6.25, 12.5 and 25 µg), twice-daily inhaled VI (6.25 µg) or placebo using a DPI. The VI treatment in asthmatics resulted in a statistically significant ($P<0.001$ for all doses) increase on day 7 in trough FEV₁ and weighted mean 24-hour FEV₁ versus placebo. The differences from placebo for trough FEV₁ with once-daily VI were 94 mL (95% CI =49–140 mL), 102 mL (95% CI =57–147 mL) and 125 mL (95% CI =80–170 mL) for 6.25, 12.5 and 25 µg doses, respectively. The 6.25 µg VI twice-daily dose resulted in 140 mL (95% CI =95–185 mL) improvement in trough FEV₁ compared to placebo.¹⁹ Non-inferiority between once-daily versus twice-daily VI dosing was also shown.¹⁹

A recent large trial children aged 5–11 years (N=456) with persistent asthma symptoms inadequately controlled on an ICS were randomized to once-daily inhaled VI (6.25, 12.5 or 25 µg), and this was compared to placebo over 4 weeks. It demonstrated safety but failed to show an improvement from baseline in trough FEV₁ for any of the VI doses tested.²⁰ Adult asthmatic patients uncontrolled on an ICS (N=347) were given once-daily VI (25 µg) for 12 weeks and were compared to those given twice-daily SAL or placebo. Researchers noted the improvement in FEV₁ of 359±42.9 mL with VI, 283±41.9 mL with SAL and 289±42.9 mL for placebo.²¹ The increase in FEV₁ was not statistically significantly different between VI and placebo. Overall, these data suggest that there is a variable response to inhaled VI in adult patients with persistent symptoms already on an ICS and even less efficacy of VI in asthmatic children on an ICS.

The use of FF and VI in asthma

Pharmacodynamic, pharmacokinetic and safety data have been tested with inhaled FF/VI in several populations, including healthy Chinese and Japanese, in patients simultaneously on ketoconazole and in patients with renal and hepatic impairment.^{22–25} Stable pharmacokinetics and pharmacodynamics and no safety concerns over the use of inhaled FF/VI were found in these studies. Allergen and methacholine challenge tests were used in 27 patients randomized to inhaled FF (100 µg), VI (25 µg), FF (100 µg)/VI (25 µg) or placebo.²⁶ Using the allergen challenge to test early asthmatic response (EAR) and airway hyperresponsiveness (AHR), researchers found a decrease in FEV₁. Using the mean 0–2 hours post allergen challenge FEV₁, the least decrease was reported with the pre-challenge dosing of the

Table 4 Major clinical trials with VI in asthma

Study	Trial number	N	Drugs (μg)	Design	Results (doses in μg)
Kempford et al¹⁷	NCT00469040; NCT00463697; NCT00519376; NCT00702910	36, 22 and 24	VI (25) or VI (50) or VI (100) or P all daily and VI (25) or VI (50) or VI (100) or P single dose and VI (6.25) or VI (25) or VI (100) or P all single dose, all by DPI	Healthy subjects (36) between 18 and 55 years old, SC, PC, R, DB, PG, $\times 14$ days and persistent asthmatics (22) ≥ 18 years old, MC, R, DB, PC, XO, single dose and persistent asthmatics (24) between 18 and 55 years old, MC, R, DB, PC, XO, single dose	VI rapidly absorbed maximal concentration between 5 and 10 minutes. No significant changes in vital signs, 12-lead ECG or blood chemistry changes were noted with VI. All doses of VI resulted in increases in FEV ₁ within 5 minutes and lasted at least 24 hours
Lötvald et al²¹	NCT01181895	347	VI (25) daily SAL (50) bid or P, all by DPI	Adult asthmatics uncontrolled by ICS alone; MC, R, PC, DB, DD, $\times 12$ weeks	VI, SAL and P all showed substantial improvement in 24-hour weighted mean FEV ₁ after 12 weeks without statistically significant differences. Low rates of AEs compared to P The adjusted mean change from baseline in evening PEF averaged over the 4-week treatment phase showed no significant difference between VI and P. No difference was also seen in trough FEV ₁ between VI and P. VI resulted in an additional 0.6 rescue-free days and 0.7 symptom- free days per week compared to P. AEs were slightly higher with VI (28%–33%) versus P (22%)
Oliver et al²⁰	NCT01573767	456	VI (6.25, 12.5 or 25) or P Daily, all by DPI, all replaced their ICS with FP (100) bid during 4-week run-in phase	Children aged 5–11 years with persistent asthma on ICS; MC, R, DB, PC, PG, $\times 4$ - and 1-week follow-up	A VI dose–response effect ($P=0.037$) was seen on improving trough FEV ₁ . Statistically significant ($P\leq 0.016$) increases in mean FEV ₁ relative to P were seen for VI doses (12, 25 and 50). Prolonged bronchodilation was seen for at least 24 hours with VI All VI doses had significant ($P<0.001$) increase in weighted mean 24-hour FEV ₁ compared to P. Low incidence of AEs with VI (5%–9%) without evidence of dose dependence. P AEs were 18%
Lötvald et al ¹⁸	NCT00600171	614	VI (3, 6.25, 12.5, 25 or 50) or P qpm, by DPI	≥ 12 -year-old symptomatic asthmatics on stable ICS dose; MC, R, DB, P, dose-ranging study, $\times 28$ days	Statistically significant ($P\leq 0.016$) increases in mean FEV ₁ relative to P were seen for VI doses (12, 25 and 50). Prolonged bronchodilation was seen for at least 24 hours with VI All VI doses had significant ($P<0.001$) increase in weighted mean 24-hour FEV ₁ compared to P. Low incidence of AEs with VI (5%–9%) without evidence of dose dependence. P AEs were 18%
Sterling et al ¹⁹	NCT00980200	75	VI (6.25) daily or VI (6.25) bid or VI (12.5) daily or VI (25) daily or P, all by DPI	≥ 18 -year-old asthmatics on stable dose ICS; MC, R, DB, PC, XO, $\times 7$ days	Statistically significant ($P\leq 0.016$) increases in mean FEV ₁ relative to P were seen for VI doses (12, 25 and 50). Prolonged bronchodilation was seen for at least 24 hours with VI All VI doses had significant ($P<0.001$) increase in weighted mean 24-hour FEV ₁ compared to P. Low incidence of AEs with VI (5%–9%) without evidence of dose dependence. P AEs were 18%
Oliver et al ⁷¹	NCT01453296	28	VI (25) or P single dose and VI (25) or P daily, all by DPI	Children aged 5–11 years with persistent asthma on ICS; MC, R, DB, PC, XO, single dose then 7 days later, once-daily dosing, $\times 7$ days	All ages showed similar VI pharmacokinetics. No laboratory or ECG abnormalities. No change in PEF from day 1 to day 14

Notes: References in bold are key studies; bid, twice daily; qpm, daily evening.

Abbreviations: AEs, adverse events; DB, double blind; DD, double dummy; DPI, dry powder inhaler; ECG, electrocardiogram; FEV₁, forced expiratory volume in 1 second; FP, fluticasone propionate; ICS, inhaled corticosteroid; MC, multicenter; P, placebo; PC, placebo controlled; PEF, peak expiratory flow; PG, parallel group; R, randomized; SAL, salmeterol; SC, single center; VI, vilanterol trifenate; XO, crossover.

combination FF/VI inhaler (-0.614 L, 95% CI $=-0.858$ to -0.370) and the greatest decrease was after placebo inhaler (-1.091 L, 95% CI $=-1.344$ to -0.837). The methacholine challenge test was used in these patients to model late asthmatic response (LAR) and AHR at 24 hours. Weighted mean FEV₁ 4–10 hours post challenge was reduced after placebo (-466 mL, 95% CI $=-589$ to -343) but actually increased with FF (100 μg ; 18 mL, 95% CI $=-89$ to 125)

and with FF (100 μg)/VI (25 μg ; 18 mL, 95% CI $=-89$ to 124). It was also improved compared to placebo with VI (25 μg ; -298 mL, 95% CI $=-415$ to -181).²⁶ The use of the combined FF/VI provided statistically significant protection against the EAR of AHR compared to its components alone and to placebo. There was also statistically significant protection with combination FF/VI therapy when compared to placebo and VI alone against the LAR of AHR.

Cytochrome P450 3A4 (CYP3A4) is the major hepatic enzyme responsible for metabolizing FF by ester hydrolysis with the formation of the 17 beta-carboxylic acid and loss of the *S*-fluoro-methyl-carbithioate.^{24,27} FF is also believed to be a substrate for the P-glycoprotein (PgP) efflux transporter, and enterocytes may have a major metabolic effect on FF in the gastrointestinal track.²⁷ The hepatic enzyme CYP3A4 also plays a major role in the metabolism of VI by *O*-dealkylation.²⁸ It is also believed to be a substrate for PgP when in the gastrointestinal system.²⁴ Ketoconazole is a probe used to assess the potential effect of CYP3A4 metabolic inhibition, and it also has inhibitory effects on PgP.²⁴ Coadministration of repeat doses of ketoconazole 400 mg daily and inhaled VI (25 µg) alone had no pharmacodynamic or pharmacokinetic effect on VI. When 11 days of 400 mg oral ketoconazole daily was coadministered with inhaled FF (200 µg)/VI (25 µg) from days 5 to 11, no statistical or clinical effect was seen on heart rate or minimal potassium levels.²⁴ There was a 27% decrease in 24-hour weighted mean serum cortisol levels (treatment ratio =0.73, 90% CI=0.62–0.86). An increase in the FF area under the plasma concentration 0–24-hour curve by 36% with ketoconazole (90% CI =16%–59%) was reported. The area under the plasma concentration 0–24-hour VI curve increased by 65% (90% CI =38%–97%).²⁴ Table 5 summarizes the major pharmacokinetic parameters of FF and VI that allow once-daily dosing for this inhaled fixed combination medication.

Table 6 summarizes the major clinical trials evaluating pharmacokinetics, safety and efficacy of FF/VI given by DPI in asthmatic patients. Large randomized double-blind clinical trials have shown improved FEV₁ and PEF measures by treatment with FF/VI compared to placebo or the same or better measures with active control agents such as inhaled FP and FP with the LABA SAL twice daily.^{29–36} These clinical trials lasted from 2 to 52 weeks and evaluated efficacy and safety. Two trials each of 12-week duration have confirmed the efficacy of FF (100–200 µg)/VI (25 µg) given daily by DPI in Asian asthmatic patients compared to placebo³⁷ and

compared to the active comparator FP using PEF measures of efficacy.³⁸

An observational study from Italian National Health Service data used propensity score matching on baseline covariates of gender, age, FEV₁ and comorbidities on 40 adult asthmatic patients. They were treated with FF (100 µg)/VI (25 µg) by DPI once daily or beclomethasone dipropionate/formoterol (BEC/F) inhalation twice daily.³⁹ The BEC/F-treated group had 0.28 (±0.12) days of hospitalization, and those treated with FF/VI had 0.08 (±0.04) days of hospitalization ($P=0.09$) during the 12-week analysis period. Both the number of physician visits and the number of specialist visits were statistically reduced in the FF/VI-treated group compared to the BEC/F-treated group.³⁹ Another small comparison study (N=30) in Japan evaluated BUD (160 µg)/F (4.5 µg) two puffs twice daily and one additional inhalation as needed of BUD/F each day versus FF (100 µg)/VI (25 µg) by DPI daily over 4 weeks in asthmatics ≥20 years who required an ICS.⁴⁰ Both drug combinations showed statistically significant ($P<0.001$) improvement in the asthma control questionnaire during the 4 weeks with greater improvement in the scores with the BUD/F-treated group. Both groups also showed decreases ($P<0.001$) in fractional exhaled nitric oxide (FeNO) from baseline to week 4 with the levels in the BUD/F group reduced greater ($P<0.001$) than the FF/VI-treated group. The use of a fixed-dose ICS/LABA as a rescue medication in this study goes against historical dogma of using SABA agents as rescue medication in asthma but is in the GINA guidelines (Table 1). In addition, direct comparisons between different combinations of ICS/LABA beg the question of dosage equivalence. In this study, perhaps the comparator should have been FF (200 µg)/VI (25 µg) as a high-dose ICS as opposed to the low-dose FF (100 µg)/VI (25 µg) combination.

The asthma–COPD overlap syndrome (ACOS) is an asthma phenotype that shares features of both asthma and traditional COPD.^{1,41} A small (N=16) open-label, randomized, crossover study of patients with ACOS in Japan compared

Table 5 Pharmacokinetics of FF and VI

Drug	Mean absorption time (IN) (hours)	Absolute bioavailability (IN) (%)	t _{max} (IN) (hours)	t _{1/2} beta (hours)	VD (IN) (L)
FF	10.53 (8.52–13.01)	6.3–18.4; 15.2 (12.6–18.4)	1.0 (0.08–4.00) to 0.08 (0.08–1.50)	23.7 (20.8–26.9) (IN); 15.4 (13.1–18.2) (IV)	661 (546–800)
VI	0.659 (0.286–1.517)	10–12; 27.3 (21.6–34.6)	0.150 (0.08–0.17) to 0.100 (0.08–0.18)	2.47 (1.65–3.70) (IN); 2.40 (1.65–3.48) (IV)	165 (129–211)

Notes: Data are mean (90% CI); t_{max}, time to maximum observed concentration (inhaled); t_{1/2} beta, terminal elimination half-life. Data from.^{10,70,72,73}

Abbreviations: CI, confidence interval; FF, fluticasone furoate; IN, inhaled dose; IV, intravenous dose; L, liters; VD, volume of distribution at steady state; VI, vilanterol trifenate.

Table 6 Major clinical trials with FF/VI in asthma

Study	Trial number	N	Drugs (μg)	Design	Results (doses in μg)
Allen et al ²⁴	NCT01086410	185	FF (100)/VI (25) or FF (200)/VI (25) or P by DPI or P by DPI plus 10 mg Pred oral last 7 days	12–65-year-old asthmatic patients; MC, R, PC, DB, PG, DD, all daily doses $\times 6$ weeks	No differences (non-inferior) in 24-hour weighted mean serum or urinary cortisol levels between FF/VI at either dose and P. Pred substantially reduced 24-hour weighted mean serum cortisol compared to P
Woodcock et al ²⁶	NCT01147848	806	FF (100)/VI (25) qpm or FF (250)/SAL (50) bid by DPI	≥ 12 -year-old asthmatic patients on stable ICS; MC, R, DB, DD, PG, $\times 24$ weeks	Significant improvement from baseline seen in 0–24-hour weighted mean FEV ₁ after 24-week treatment with both FF/VI qpm or FF/SAL bid. No difference in asthma control measures or exacerbations
Busse et al ³⁴	NCT01018186	503	FF (100)/VI (25) qpm or FF (200)/VI (25) qpm or FF (500) bid by DPI	≥ 12 -year-old asthmatic patients on ICS; MC, R, DB, DD, PG, $\times 52$ weeks	Exacerbation rates were FF (100)/VI (25) (1%), FF (200)/VI (25) (3%) and FF (500) (3%) during the study. Statistically significant ($P \leq 0.006$) cortisol suppression seen with FF compared to both FF/VI doses at weeks 12 and 28 but not at week 52. No clinically important glucose, potassium, ECG or ophthalmic changes were noted
O'Byrne et al ³²	NCT01134042	586	FF (200)/VI (25) qpm or FF (200) qpm or FF (500) bid by DPI	≥ 12 -year-old asthmatic patients on ICS; MC, R, DB, DD, PG, $\times 24$ weeks	FF/VI significantly ($P < 0.001$) improved both trough and weighted mean (0–24 hours) FEV ₁ compared to both FF and FF alone. AEs were similar between groups
Bateman et al ³¹	NCT01086384	2,019	FF (100)/VI (25) or FF (100) daily qpm by DPI	≥ 12 -year-old asthmatic patients on ICS; MC, R, DB, PG, $\times 24$ –78 weeks	FF/VI compared to FF alone delayed onset of first severe asthma experience exacerbation ($P \leq 0.05$). Significantly ($P < 0.001$) greater trough FEV ₁ improvement with FF/VI than FF alone. Both were well tolerated with similar AEs
Bernstein et al ²⁹	NCT01686633	1,039	FF (100) or FF (100)/VI (25) or FF (200)/VI (25) qpm daily by DPI	≥ 12 -year-old asthmatic patients on ICS; MC, R, DB, stratified, PG, $\times 12$ weeks	Weighted mean FEV ₁ (0–24 hours) was significantly ($P < 0.01$) increased by both doses of FF/VI compared to FF alone. Trough FEV ₁ percentage of rescue-free 24-hour periods and morning/evening PEF were also improved. Small numerical improvements occurred with FF (200)/VI (25) compared to FF (100)/VI (25). All treatments were well tolerated
Kempford et al ³⁵	NCT01287065	26	FF (100)/VI (25) qpm or FF (100)/VI (25) qam or P by DPI	18–70-year-old asthmatic patients on stable ICS; SC, R, DB, PC, XO, daily dose of FF/VI given qam or qpm with P given the opposite qam/qpm or P given bid $\times 14$ days	Both, morning and evening FF/VI, increased weighted mean FEV ₁ . Both dosing times produced comparable improvements in lung function
Allen et al ²⁵	NCT01266941 and NCT01266980	35	FF (200)/VI (25) or FF (100)/VI (25) by DPI	Two studies, OL, PG, daily doses in: 1) mild to moderate hepatic impaired patients or healthy matched patients, all daily dose $\times 7$ days; 2) severe renal impaired (CrCl < 30 mL/min) patients or healthy matched patients, all daily dose $\times 7$ days	No effect on VI maximal concentrations or area under the concentration curve for 24 hours in liver or renal impaired patients. No difference in heart rate, serum potassium or 24 hour serum cortisol levels seen

(Continued)

Table 6 (Continued)

Study	Trial number	N	Drugs (μg)	Design	Results (doses in μg)
Oliver et al ²⁵	NCT01128569	52	FF (100) or FF (100)/VI (25) or P by DPI	18–65-year-old asthmatics; MC, R, DB, PC, XO, daily dose $\times 28$ days	Weighted mean FEV ₁ for the 2-hour post-allergen challenge was improved by FF and FF/VI compared to P. No difference was seen between FF and FF/VI
Kempford et al ²⁴	NCT01165125 and NCT00866515	20 and 18	1) Keto 400 mg or P oral daily $\times 6$ days on day 5 VI (25) $\times 1$ dose by DPI and 2) Keto 400 mg or P oral daily $\times 11$ days with FF (200)/VI (25) daily days 4–11 by DPI	18–52-year-old healthy subjects; SC, R, DB, XO, all doses were daily	Oral Keto is known as CYP3A4 and Pgp inhibitors. No major effect of Keto on VI pharmacodynamics was seen. Maximal levels and area under the curve (0–24 hours) were increased approximately twofold by Keto on FF (36%) and VI (65%). No effect on maximal heart rate or minimal potassium levels was seen when Keto was given with FF/VI. A 27% decrease in 24-hour weighted mean serum cortisol levels was noted
Nakahara et al ²³	NCT00625196; NCT00964249; NCT00972673	48, 32 and 16	FF (200, 400 or 800) or P and VI (12.5 or 25) and FF (800) or VI (50) or FF (800)/VI (50) by DPI	Healthy adult Japanese males, single dose; then 4-day washout; then daily dose days 5–11 (7 days) and single dose daily $\times 7$ days and single dose	Peak serum concentrations of FF and VI were up to two times higher compared to single doses. No clinically significant difference in VI or FF levels when administered together compared to alone. Repeat doses of FF affected weighted mean (0–24 hours) serum cortisol with FF (200, 400 and 800) resulting in respective reductions from placebo of 32%, 38% and 97% respectively. No safety concerns were seen
Oliver et al ²⁶	NCT01128595	26	FF (100) or VI (25) or FF (100)/VI (25) or P by DPI	18–65-year-old asthmatic patients; MC, R, DB, PC, XO, daily dose qam $\times 21$ days; allergen challenge test and MCT	Treatment with FF, VI or FF/VI all reduced the early decrease in FEV ₁ with allergen challenge test 0–2 hours and 24 hours compared to P on day 21. Same protection was seen with MCT for FF, VI or FF/VI on day 22
Oliver et al ³³	None given	26	FF (100)/VI (25) or FF (100) daily by DPI	5–11-year-old patients with mild asthma controlled by ICS, R, DB, XO, stratified by age, $\times 14$ days	No difference was seen in primary outcomes including AEs, laboratory measures, heart rate, blood pressure, PEF or ECG between FF/VI and FF
Bleecker et al ³⁰	NCT01165138	609	FF (100)/VI (25) or FF (100) or P all daily qpm by DPI	≥ 12 -year-old asthmatic patients; MC, R, DB, PG, $\times 12$ weeks	Both FF/VI and FF significantly ($P < 0.003$) increased trough and weighted mean (0–24 hours) FEV ₁ compared to P. No statistical difference between FF/VI and FF in FEV ₁ . The percentage of rescue inhaler-free 24-hour periods 10.6% greater with FF/VI than FF alone and 19.3% greater with FF/VI than P
Lin et al ³⁸	NCT10498653	309	FF (200)/VI (25) qpm or FP (500) bid by DPI	≥ 12 -year-old asthmatic patients from the People's Republic of China, South Korea and the Philippines; MC, R, DB, DD, PG, $\times 12$ weeks	Significantly greater change from baseline on evening PEF by FF/VI compared to FP ($P < 0.001$). No difference in AEs
Chen et al ²²	NCT01711463	16	FF (50)/VI (25) or FF (100)/VI (25) or FF (200)/VI (25) or P qam daily by DPI	18–45-year-old healthy Chinese subjects; SC, R, DB, PC, XO, $\times 7$ days	Reductions compared to P in weighted mean serum cortisol (0–24 hour) levels for day 7 were seen for FF (100)/VI (25) and FF (200)/VI (25) compared to P. FF/VI was safe and well tolerated
Lin et al ³⁷	NCT01498679	307	FF (100)/VI (25) or P daily all by DPI	≥ 12 -year-old patients with Asian ancestry and asthmatics on ICS; MC, R, DB, PC, PG, $\times 12$ weeks	Significant ($P < 0.001$) improvement in change from baseline for FF/VI versus P in evening PEF. Greater percentage of symptom-free 24-hour periods with FF/VI than P. ADEs were 35% for FF/VI and 31% for P

Hozawa et al ⁴⁰	None given	30	BUD (320)/F (9) bid plus as-needed BUD (160)/F (4.5) or FF (100)/VI (25) qpm plus as-needed procaterol, all by DPI	≥20-year-old Japanese asthmatics on ICS; SC, R, OL, ×4 weeks	BUD/F and FF/VI both showed improvement in airway inflammation, FEV ₁ , resonance frequency exhaled nitric oxide and asthma control scores, but FF/VI improvement seemed to plateau, while BUD/F did not. The use of a single as-needed dose of BUD/F was well tolerated
Dal Negro et al ³⁹	None given	117	BEC (100)/F (6) bid or FF (92)/VI (22) daily, all by DPI	Adult asthmatic patients; observational, retrospective with propensity score matching, ×12 weeks	The number of relapses per patient was 0.53 (±0.12) for the BEC/F treatment group and 0.28 (±0.07) for the FF/VI group ($P=0.12$). Less hospitalizations ($P=0.11$), specialist visits ($P<0.001$) and general physician visits ($P<0.001$) were seen in the FF/VI group compared to the BEC/F-treated group. The mean cost of hospitalizations per patient was less but not significant for the FF/VI group
Ishiura et al ⁴²	None given	16	FF (200)/VI (25) qam or FP (500)/SAL (50) bid, all by DPI	Adult 59–87-year-old Japanese patients with ACOS; OL, R, XO, ×12 weeks	The trough FEV ₁ was significantly ($P<0.01$) higher after FF/VI than at baseline. No significant change in FEV ₁ was seen with FP/SAL treatment. Each spirometry parameter was significantly ($P<0.05$) higher after FF/VI treatment than values found with FP/SAL

Notes: References in bold are key studies; bid, twice daily; qam, daily morning; qpm, daily evening.

Abbreviations: ACOS, asthma-COPD overlap syndrome; ADE, adverse drug event; AEs, adverse events; BEC/F, beclomethasone dipropionate/formoterol; BUD/F, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; CYP, cytochrome P450; DB, double blind; DD, double dummy; DPI, dry powder inhaler; ECG, electrocardiogram; FEV₁, forced expiratory volume in 1 second; FF, fluticasone furoate; FP, fluticasone propionate; ICS, inhaled corticosteroid; Keto, ketoconazole; MC, multicenter; MCT, methacholine challenge test; OL, open label; PC, placebo controlled; PEF, peak expiratory flow; PG, parallel group; Pgp, P-glycoprotein; Pred, prednisolone; R, randomized; SAL, salmeterol; SC, single center; VI, vilanterol trifenatate; XO, crossover.

once-daily FF (200 µg)/VI (25 µg) versus FP (500 µg)/SAL (50 µg) twice daily for 4-week treatment periods.⁴² The mean value of FEV₁ was 1.33 L (±1.29) during the run-in period, 138 L (±0.39) after the FP/SAL treatment and 1.47 (±0.38) L after the FF/VI treatment. The mean value of FEV₁ was significantly ($P<0.01$) greater in the FF/VI treatment group compared to the run-in period in these patients with ACOS. Although a small trial of short duration, it is one of the few pharmacological trials in patients with ACOS and the only randomized trial evaluating the FF/VI combination inhaler in patients with ACOS phenotype.

A large pragmatic study evaluating FF (100 or 200 µg)/VI (25 µg) inhaler use versus existing asthma maintenance therapies is ongoing. The Salford Lung Study is a randomized and controlled trial started before FF/VI inhalers were approved for asthma treatment. It utilizes the Salford electronic medical record to give near real-time data collection and monitoring of safety data at 66 primary care sites in and around Salford and South Manchester, England.⁴³ The data from this study when available will complement the more standard double-blind, randomized, controlled trials evaluating real-world efficacy and obtaining risk/benefit information on inhaled FF/VI.

When East Asian patients were compared to non-East Asian patients from the large randomized, double-blind, multicenter clinical trials in a prespecified subgroup analysis, both FF (100 or 200 µg)/VI (25 µg) dose combinations were as effective in improving FEV₁ compared to placebo as in non-East Asian patients.⁴⁴ A systematic review with meta-analysis of seven published trials (N=5,668) evaluating inhaled FF/VI in asthmatic patients was recently performed.⁴⁵ The combination therapy of FF (100 or 200 µg)/VI (25 µg) daily increased trough FEV₁ in asthmatics treated longer than 8 weeks compared to either FP twice daily or FF daily alone. Three of the seven trials compared FF (100 or 200 µg)/VI (25 µg) doses to FF (100 µg) once daily and showed a significant ($P\leq 0.001$) increase in trough FEV₁ of 90 mL (95% CI =60–120 mL) with the combination inhaler compared to FF alone.⁴⁵

Medication adherence with inhalers

Medication adherence or following the medication plan is a significant problem and factor in the treatment of chronic diseases.⁴⁶ Dosing frequency has a major effect on the rate of nonadherence of medication in chronic diseases.⁴⁷ When medications are given twice daily compared to once daily, the adherence rates were significantly lower, with regimen adherence reduced by 13.1% and timing adherence reduced

by 26.7% compared to once daily.⁴⁷ The adherence rates fall 23.1% for regimen adherence and 54.2% for timing adherence when medications are given four times daily compared to daily dosing. Nonadherence to treatment is associated with poor baseline asthma control.^{48,49} The nonadherence rates among asthmatic patients range between 30% and 70%, and because of this the assessment of medication adherence is a critical part of evaluating the difficult to treat asthma patient.^{50,51} Integrated and innovative approaches to patients are needed to improve medication adherence in difficult asthmatic patients.⁵² Once-daily medications and the combination of an ICS with a LABA in a single inhaler are associated with improved medication adherence compared to that of an ICS alone.^{53,54} Better medication adherence must be addressed and will improve health outcomes and asthma disease control.^{55,56}

In addition to being a daily combination dosing asthma maintenance medication, Breo Ellipta (GSK) utilizes the Ellipta delivery system. The Ellipta dry powder system (GSK, UK and Japan) has been shown to be easy to use and preferred over the Breezhaler (Novartis Pharma UK, Japan) in device-naïve Japanese volunteers.⁵⁷ When semi-structured, in-depth, qualitative interviews were conducted on asthma and COPD patients after using Ellipta (GSK, Germany) dry powder inhalation systems, the Ellipta device was associated with the highest patient satisfaction and preference.⁵⁸ Patient preference for the Ellipta device was also demonstrated in 287 COPD patients randomized to the Ellipta or Diskus DPIs.⁵⁹ The Ellipta device was significantly preferred ($P < 0.001$) over the Diskus device in all categories. Overall inhaler preference was 67% for the Ellipta device and 31% for the Diskus.⁵⁹ Once-daily dosing with the FF/VI Ellipta device and its high patient preference are also likely to contribute to improved asthma medication adherence.

To date, a large amount of clinical trial data exists supporting the efficacy and safety of the use of inhaled FF/VI by DPI for asthma maintenance treatment. The combination ICS/LABA of FF/VI fits well into the GINA guidelines starting as early as step 3.¹ Studies looking at a fixed-dose triple-combination inhaler with FF, VI and the LAMA UMEC are ongoing in healthy volunteers, being developed for COPD indication and could be evaluated in asthmatic patients.⁶⁰

Conclusion

The DPI inhaler, FF/VI, is a fixed combination of two strengths of FF (100 or 200 µg) both with VI (25 µg) used as a maintenance treatment in asthmatic patients not controlled on just an ICS therapy alone. The doses of FF cover low- and high-dose ICS categories and fit nicely into the current GINA

asthma treatment guidelines. Clinical trials have focused on each of the components of the combination inhaler. Efficacy and safety were demonstrated with inhaled FF in asthmatic patients. Similarly, efficacy and safety were demonstrated in clinical trials in adolescent and adult asthmatic patients on an ICS with adding inhaled VI but not in children aged 5–11 years. The data supporting the combined use of FF/VI in asthmatic patients requiring ICS are strong and document its efficacy and safety in long-term, large and randomized clinical trials in adolescents and adults. Pharmacokinetics and pharmacodynamics have been well studied and have demonstrated limited clinically important drug interactions (eg, ketoconazole) and minimal alterations from renal and liver impairments. Limited efficacy data with inhaled FF/VI exist for asthmatic children (<12 years). Further studies on asthmatic children and various asthma phenotypes such as patients with ACOS are needed to better understand the full spectrum of the use of inhaled fixed combination FF/VI in the maintenance treatment of asthma.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Asthma GINA Guidelines [homepage on the Internet]. *Pocket Guide for Asthma Management and Prevention*. 2016. Available from: www.ginasthma.org. Accessed September 1, 2016.
2. US FDA [database on the Internet]. 2016; Available from: https://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed September 1, 2016.
3. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. *BMJ*. 1993; 306(6884):1034–1037.
4. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, Group SS. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. *Chest*. 2006;129(1):15–26.
5. Peters SP, Bleecker ER, Canonica GW, et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. *N Engl J Med*. 2016; 375(9):850–860.
6. Stempel DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. *N Engl J Med*. 2016; 374(19):1822–1830.
7. Stempel DA, Szeffler SJ, Pedersen S, et al. Safety of adding salmeterol to fluticasone propionate in children with asthma. *N Engl J Med*. 2016; 375(9):840–849.
8. Bush A, Frey U. Safety of long-acting beta-agonists in children with asthma. *N Engl J Med*. 2016;375(9):889–891.
9. Syed YY. Fluticasone furoate/vilanterol: a review of its use in patients with asthma. *Drugs*. 2015;75(4):407–418.
10. Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. *Clin Pharmacokinet*. 2013; 52(1):37–42.
11. Woodcock A, Bateman ED, Busse WW, et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. *Respir Res*. 2011;12:132.

12. Kempson RD, Bal J, Baines A, Renaux J, Ravindranath R, Thomas PS. The efficacy of fluticasone furoate administered in the morning or evening is comparable in patients with persistent asthma. *Respir Med*. 2016;112:18–24.
13. Woodcock A, Lotvall J, Busse WW, et al. Efficacy and safety of fluticasone furoate 100 mg and 200 mg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. *BMC Pulm Med*. 2014;14:113.
14. Lee LA, Yang S, Kerwin E, Trivedi R, Edwards LD, Pascoe S. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. *Respir Med*. 2015;109(1):54–62.
15. Yang S, Lee L, Mallett S, Ayer J, Wolstenholme A, Pascoe S. A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers. *Adv Ther*. 2015;32(2):157–171.
16. Aparici M, Gavaldà A, Ramos I, et al. In vitro and in vivo pre-clinical profile of abediterol (LAS100977), an inhaled long-acting beta2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol. *Eur J Pharmacol*. 2016;770:61–69.
17. Kempson R, Norris V, Siederer S. Vilanterol trifenate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. *Pulm Pharmacol Ther*. 2013;26(2):256–264.
18. Lötvall J, Bateman ED, Bleecker ER, et al. 24-h duration of the novel LABA vilanterol trifenate in asthma patients treated with inhaled corticosteroids. *Eur Respir J*. 2012;40(3):570–579.
19. Sterling R, Lim J, Frith L, Snowise NG, Jacques L, Haumann B. Efficacy and optimal dosing interval of the long-acting beta(2) agonist, vilanterol, in persistent asthma: a randomised trial. *Respir Med*. 2012;106(8):1110–1115.
20. Oliver AJ, Covar RA, Goldfrad CH, et al. Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy. *Respir Res*. 2016;17:37.
21. Lötvall J, Bateman ED, Busse WW, et al. Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. *J Negat Results Biomed*. 2014;13(1):9.
22. Chen X, Zheng X, Jiang J, et al. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects. *Pharmacotherapy*. 2015;35(6):586–599.
23. Nakahara N, Wakamatsu A, Kempson R, et al. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. *Int J Clin Pharmacol Ther*. 2013; 51(8):660–671.
24. Kempson R, Allen A, Bal J, Rubin D, Tombs L. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenate in healthy subjects. *Br J Clin Pharmacol*. 2013;75(6):1478–1487.
25. Allen A, Davis A, Hards K, Tombs L, Kempson R. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination. *Clin Ther*. 2012;34(12):2316–2332.
26. Oliver A, Bjermer L, Quinn D, et al. Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. *Allergy*. 2013;68(9):1136–1142.
27. Hughes SC, Shardlow PC, Hollis FJ, et al. Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. *Drug Metab Dispos*. 2008;36(11):2337–2344.
28. Harrell AW, Siederer SK, Bal J, et al. Metabolism and disposition of vilanterol, a long-acting beta(2)-adrenoceptor agonist for inhalation use in humans. *Drug Metab Dispos*. 2013;41(1):89–100.
29. Bernstein DI, Bateman ED, Woodcock A, et al. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. *J Asthma*. 2015;52(10):1073–1083.
30. Bleecker ER, Lotvall J, O'Byrne PM, et al. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. *J Allergy Clin Immunol Pract*. 2014;2(5):553–561.
31. Bateman ED, O'Byrne PM, Busse WW, et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. *Thorax*. 2014;69(4):312–319.
32. O'Byrne PM, Bleecker ER, Bateman ED, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. *Eur Respir J*. 2014;43(3):773–782.
33. Oliver A, VanBuren S, Allen A, et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. *Clin Ther*. 2014;36(6):928e921–939e921.
34. Busse WW, O'Byrne PM, Bleecker ER, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial. *Thorax*. 2013;68(6):513–520.
35. Kempson RD, Oliver A, Bal J, Tombs L, Quinn D. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. *Respir Med*. 2013;107(12): 1873–1880.
36. Woodcock A, Bleecker ER, Lotvall J, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. *Chest*. 2013;144(4):1222–1229.
37. Lin J, Tang H, Chen P, et al. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist. *Allergy Asthma Proc*. 2016;37(4):302–310.
38. Lin J, Kang J, Lee SH, et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. *Respir Med*. 2015;109(1): 44–53.
39. Dal Negro RW, Distant C, Bonadiman L, Turco P, Iannazzo S. Fluticasone furoate/vilanterol 92/22 mg once-a-day vs beclomethasone dipropionate/formoterol 100/6 mg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma. *Multidiscip Respir Med*. 2016;11:20.
40. Hozawa S, Terada M, Haruta Y, Hozawa M. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy. *Pulm Pharmacol Ther*. 2016; 37:15–23.
41. Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. *Expert Rev Clin Pharmacol*. 2013;6(2):197–219.
42. Ishiura Y, Fujimura M, Shiba Y, Ohkura N, Hara J, Kasahara K. A comparison of the efficacy of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome. *Pulm Pharmacol Ther*. 2015;35:28–33.
43. Woodcock A, Bakerly ND, New JP, et al. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma. *BMC Pulm Med*. 2015;15:160.
44. Gross AS, Goldfrad C, Hozawa S, et al. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre phase IIb/III trials. *BMC Pulm Med*. 2015;15:165.
45. Rodrigo GJ, Plaza V. Once-daily fluticasone furoate and vilanterol for adolescents and adults with symptomatic asthma: a systematic review with meta-analysis. *Ann Allergy Asthma Immunol*. 2016;116(6): 565–570.
46. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. *J Behav Med*. 2008; 31(3):213–224.
47. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. *J Manag Care Pharm*. 2012;18(7): 527–539.
48. Lindsay JT, Heaney LG. Non-adherence in difficult asthma and advances in detection. *Expert Rev Respir Med*. 2013;7(6):607–614.
49. Fischer J, Wimmer A, Mahlich J. [Medication adherence in asthma therapy – a structured review]. *Pneumologie*. 2013;67(7):406–414.

50. Lindsay JT, Heaney LG. Nonadherence in difficult asthma – facts, myths, and a time to act. *Patient Prefer Adherence*. 2013;7:329–336.
51. Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem? *Ann Allergy Asthma Immunol*. 1997;79(3):177–185; quiz:185–176.
52. Bender B, Milgrom H, Apter A. Adherence intervention research: what have we learned and what do we do next? *J Allergy Clin Immunol*. 2003;112(3):489–494.
53. Feehan M, Ranker L, Durante R, et al. Adherence to controller asthma medications: 6-month prevalence across a US community pharmacy chain. *J Clin Pharm Ther*. Epub 2015 Aug 20.
54. McNally KA, Rohan J, Schluchter M, et al. Adherence to combined montelukast and fluticasone treatment in economically disadvantaged African American youth with asthma. *J Asthma*. 2009;46(9):921–927.
55. Shams MR, Fineman SM. Asthma adherence: how can we help our patients do it better? *Ann Allergy Asthma Immunol*. 2014;112(1):9–12.
56. Heaney LG, Horne R. Non-adherence in difficult asthma: time to take it seriously. *Thorax*. 2012;67(3):268–270.
57. Komase Y, Asako A, Kobayashi A, Sharma R. Ease-of-use preference for the ELLIPTA(R) dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naive Japanese volunteers aged 40 years or older. *Int J Chron Obstruct Pulmon Dis*. 2014;9:1365–1375.
58. Svedsater H, Dale P, Garrill K, Walker R, Woepse MW. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. *BMC Pulm Med*. 2013;13:72.
59. Yun Kirby S, Zhu CQ, Kerwin EM, Stanford RH, Georges G. A preference study of two placebo dry powder inhalers in adults with COPD: ELLIPTA(R) dry powder inhaler (DPI) versus DISKUS(R) DPI. *COPD*. 2016;13(2):167–175.
60. Brealey N, Gupta A, Renaux J, Mehta R, Allen A, Henderson A. Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers. *Int J Clin Pharmacol Ther*. 2015;53(9):753–764.
61. Bateman ED, Bleecker ER, Lotvall J, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. *Respir Med*. 2012;106(5):642–650.
62. Lötval J, Bleecker ER, Busse WW, et al. Efficacy and safety of fluticasone furoate 100 mcg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. *Respir Med*. 2014;108(1):41–49.
63. Busse WW, Bateman ED, O'Byrne PM, et al. Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial. *Allergy*. 2014;69(11):1522–1530.
64. O'Byrne PM, Woodcock A, Bleecker ER, et al. Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. *Respir Res*. 2014;15:88.
65. Woodcock A, Bleecker ER, Busse WW, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. *Respir Res*. 2011;12:160.
66. Medley H, Orozco S, Allen A. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. *Clin Ther*. 2012;34(8):1683–1695.
67. Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. *Thorax*. 2012;67(1):35–41.
68. Bleecker ER, Bateman ED, Busse WW, et al. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. *Ann Allergy Asthma Immunol*. 2012;109(5):353e354–358e354.
69. van den Berge M, Lujik B, Bareille P, Dallow N, Postma DS, Lammers JW. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. *Allergy*. 2010;65(12):1531–1535.
70. Allen A, Bal J, Cheesbrough A, Hamilton M, Kempsford R. Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. *Br J Clin Pharmacol*. 2014;77(5):808–820.
71. Oliver A, VanBuren S, Allen A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of vilanterol, a novel inhaled long-acting beta-agonist, in children aged 5–11 years with persistent asthma: a randomized trial. *Clin Pharmacol Drug Dev*. 2014;3(3):215–221.
72. Allen RA, Wu W, Yao M, et al. Nerve regeneration and elastin formation within poly(glycerol sebacate)-based synthetic arterial grafts one-year post-implantation in a rat model. *Biomaterials*. 2014;35(1):165–173.
73. Calzetta L, Rinaldi B, Cazzola M, Matera MG. Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma. *Expert Opin Drug Metab Toxicol*. 2016;12(7):813–822.
74. Allen A, Schenkenberger I, Trivedi R, et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. *Clin Respir J*. 2013;7(4):397–406.
75. Oliver A, Quinn D, Goldfrad C, van Hecke B, Ayer J, Boyce M. Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial. *Clin Transl Allergy*. 2012;2(1):11.

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>

Dovepress

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.